Abbott Laboratories — Oct 16, 2024 release

• Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items. • Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales 2 . • Abbott now projects full-year diluted EPS on a GAAP basis of $3.34 to $3.40 and projects adjusted diluted EPS of $4.64 to $4.70, which represents an increase at the midpoint of the guidance range. • In October, Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares. • In August, Abbott announced a unique global partnership with Medtronic to collaborate on connecting Abbott's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices. • In September, Abbott announced the U.S. launch of Lingo ™ , the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness. • In September, Abbott announced a partnership with the Big Ten Conference ® to conduct a nationwide blood donation competition to help increase the U.S. blood supply. • In September, Abbott completed enrollment ahead of schedule in its VOLT-AF IDE trial, which is designed to evaluate the Volt ™ Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib). "Our results this quarter demonstrate the strength of our diversified business